The role of neoadjuvant chemotherapy for invasive bladder cancer

British Journal of Urology

Volumn 82, Issue 1, 1998, Pages 33-42

  Martinez Pineiro J A ^a   Martinez Pineiro L ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER SURVIVAL; COST BENEFIT ANALYSIS; CYSTECTOMY; DRUG TOXICITY; HUMAN; PRIORITY JOURNAL; REVIEW;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0031869836     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00674.x     Document Type: Review

References (65)

1. Yagoda A, Watson RC, Whitmore WF, Cisplatin (DDR) regimens in bladder cancer. Proc Am Soc Clin Oncol 1979; 20: 347 abstract C-231
2. Yagoda A, Chemotherapy for advanced bladder cancer. In Yagoda A, ed. Bladder Cancer. Future Direction and Treatment. New York: John Wiley and Sons 1986: 87
3. Sternberg CN, Yagoda A, Scher AI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985: 133: 403-7
4. Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate and vinblastine (CMV): effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group Study. J Clin Oncol 1985; 3: 1463-70
5. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-5
6. Raghavan D, Review: Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasive bladder cancer. Br J Urol 1988: 61: 1-6
7. Lerner SP, Skinner E, Skinner DG, Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am 1992: 19: 713-23
8. Gospodarowitz MK, Rider WD, Keen CW et al. Bladder cancer: long term follow-up results of patients treated with radical irradiation. Clin Oncol 1991: 3: 155-61
9. Soloway MS, Löpez AE, Patel J, Lu Y, Results of radical cystectomy for transitional cell carcinoma of the bladder and effect of chemotherapy. Cancer 1994: 73: 1926-31
10. Thrasher JB, Frazier HA, Robertson JE, Dodge RK, Paulson DF, Clinical variables which serve as predictors of cancerspecific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1994: 3: 1708-15
11. Prout GR, Griffin PP, Shipley Wv. Bladder cancer as a systemic disease. Cancer 1979: 43: 2532-9
12. Fagg SL, Dowson-Edwards P, Hughes MA, Latief TN, Rolfe EB, Fielding JW, Cis-diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer. Br J Urol 1984: 56: 296-300
13. Raghavan D, Neoadjuvant and classic adjuvant chemotherapy for bladder cancer. Curr Opin Urol 1991; 1: 53-6
14. Skinner DG, Daniels JR, Rüssel ÇA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145:459-67
15. Hall RR, Newling ÜW, Ramsden PD et al Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984; 56: 668-72
16. Martinez-Pineiro JA, Jiménez Leon J, Martinez-Pineiro L, Is chemotherapy a new form of radical treatment in infiltrating tumor localized to the bladder? In Murphy P. ed. Therapeutic Progress in Uroloaical Cancers. New York: Alan RLiss 1989: 583-9
17. Martinez-Pineiro JA, Martinez-Pineiro L, Es posible la conservaciön vesical en el cancer infiltrante.' Arch Esp Urol 1994: 47: 337-42
18. Simon SD, Srougi M, Primary methotrexate. vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5 year follow-up. J Urol 1994; 151: 593-7
19. Kaufman DS, Shipley WV, Griffin PP, Heny NM, Althausen AF, Eflrd TJ, Selective bladder preservation by combination treatment of invasive bladder cancer. New Enal J Med 1993; 329: 1377-82
20. Angulo JC, Sanchez Chapado M, Löpez JI, Flores N, Primary cisplatin. methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: a multivariate analysis on prognostic factors. J Urol 1987: 155: 1897-902
21. Tester W, Porter A, Asbell S et al. Combined modality program with possible organ preservation for invasive bladder carcinoma, results of RTOG protocol 85-12. Int I Rad Oncol Biol Phys 1993: 25: 783-90
22. Splinter TAW, Denis L, Restaging procedures -criteria of response and relationship between pathological response and survival. Semin Oncol 1990; 17: 606-12
23. Herr HW, The role of surgery in initial staging and follow-up. In Splinter TAW, Scher HI, eds, Neoadjuvant Chemotherapy in Invasive Bladder Cancer. Progress in Clinical and Biological Research. New York: Wiley-Liss 1990: 35-43
24. Shearer RJ, Chilver CF, Bloom HJ, Bliss JM, Horwich A, Babiker A, Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br J Urol 1988; 62: 558-64
25. Wallace DM, Raghavan D, Kelly KA ft al. Neoadjuvant (preemptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 608-15
26. Coppin C, Gospodarowicz M, James K ft al. for the National Cancer Institute of Canada Clinical Trials Group: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or radical radiation. J Clin Oncol 1996: 14: 2901-8
27. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase study. J Urol 1995: 153: 964-73
28. Malmström PU, Rintala E, Wahlqvist R, Hellström P, Hellsteen S, Hannisdal E. and Members of the Nordic Cooperative Bladder Cancer Study Group: Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I, J Urol 1996: 155: 1903-6
29. Hall RR, for the MRC Advanced Bladder Cancer Working Party EORT/GUG, Norwegian Bladder Cancer Group. Australian Bladder Cancer Study Group. Club Urolôgico Espanol de Tratamiento Oncolögico. Finnbladder. Neoadjuvant CMV Chemotherapy and Cystectomy or Radiotherapy in muscle invasive bladder cancer. First analysis of MRC/EORTC Intercontinental trial. Pror Am Soc Clin Oncol 1996: 15: 244
30. Crawford DE, Natale RB, Burton H, Southwest Oncology Group study 8710. Trial of cystectomy alone versus neoadjuvant M-VAC and cystectomy in patients with locally advanced bladder cancer (Intergroup Trial 0080)). In Splinter TAW, Scher NI, eds, Neoadjuvant Chemotherapy in Invasive Bladder Cancer. Progress in Clinical and Bioloaical Research. New York: Wiley-Liss 1990: 111-3
31. Advanced Bladder Cancer Overview Collaboration; Ghersi D, Stewart LA, Parmar C ft al. Does neoadjuvant cisplatinbased chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Rr J Urol 1995; 75: 206-1I
32. Eoehrer PJ, Einhorn EH, Elson PH ft al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992: 10: 1066-73
33. Greven KM, Spera JA, Solin EJ, Moyen T, Hanks GE, Local recurrence after cystectomy alone for bladder carcinoma. Cancer 1992; 69: 2767-9
34. Eogothetis C, Swanson D, Amato R et al. Optimal delivery of perioperative chemotherapy: Preliminary results of a randomized, prospective comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 1996; 155: 1241-5
35. Splinter TAW. 'Neoadjuvante' Chemotherapie des invasiven Blasenkarzinoms. Editorial. Akt Urol 1990: 21: 173-4
36. Splinter TAW, Sher HI. and the EORTC-GU Group. The prognostic value of the pT category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. In Splinter TAW, Scher HI, eds, Neoadjuvant Chemotherapy in Invasive Bladder Cancer. New York: Wiley-Liss 1990: 219-24
37. Schultz PK, Herr HW, Zhang ZF et al. Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994: 12: 1394-401
38. Donat SM, Herr HW, Bajorin DF et al. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy, and cystectomy for unresectable bladder cancer. J Urol 1996; 156: 368-71
39. Scher H, Herr H, Sternberg C et al. Neoadjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br J Urol 1989: 64: 250-6
40. Solsona E, Iborra I, Ricos JV, Monros JL, Dumont R, Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder. A prospective study. J Urol 1992; 147: 1513-5
41. Martinez-Pineiro JA, de la Pena J, Cisneros J, Jiménez J, Martînez-Pineiro L, Combined intravenous cyclophosphamide, adriamycin and cisplatin (CISCA) as primary treatment for patients with invasive urothelial cancer. In di Silverio F, Steg A. eds. New Trends in Bladder Cancer Chemotherapy. Rome: Acta Medica, Edizioni e Congresi 1987: 11-94
42. Hall RR, Roberts JT, Neoadjuvant chemotherapy, a method to conserve the bladder? Eur J Cancer 1991; (Suppl 2): abstract 144
43. Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L, Aggresive TURB combined with systemic chemotherapy for locally invasive TCC of the urinary bladder. A second report. Eur J Cancer 1991; (Suppl 2): abstract 605
44. nd Congresss Société Internationale d'Urologie, Seville 1991 Abstract 215
45. Hall RR, Radical TUR and Chemotherapy aiming at bladder preservation. In Villavicencio A, Fair WR, eds. Societé Internationale d'Urologie Reports: Evaluation of chemotherapy in bladder cancer. Edinburgh: Churchill livingstone 1992: 91-4
46. Herr HW, Scher HI, Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 1994; 12: 975-80
47. Sternberg CN, Arena MG, Calabresi F et al. Neoadjuvant M-VAC, methotrexate, vinblastine, doxorubicin and cisplatin for infiltrating transitional cell carcinoma of the bladder. Cancer 1993; 72: 1975-82
48. Housset M, Maulard C, Chrétien Y et al. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993: 11: 2150-7
49. Tester W, Caplan R, Heaney J et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of radiation Therapy Oncology Group Phase II trial 8802. J Clin Oncol 1996; 14: 119-26
50. Dunst J, Sauer R, Schrott KM, Kühn R, Wittekind C, Altendorf-Hofman A, Organ sparing treatment of advanced bladder cancer: a 10 year experience. Int J Rad Oncol Biol Phys 1994: 30: 261-6
51. Given RW, Parsons JT, McCarley D, Wajsman Z, Bladder sparing multimodality treatment of muscle-invasive bladder cancer: a five year follow-up. Urology 1995; 46: 499-505
52. Angulo Cuesta J, Flores Corral N, Quimioterapia sistémica con cisplatino, metotrexato y vinblastina, y preservación vesical en el cancer de vejiga T2/T3a. Actas Urol Esp 1997; 21: 28-33
53. Lerner SP, Skinner DG, Lieskowsky G et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal métastases: long-term results. J Urol 1993: 149: 758-65
54. Roehrborn CG, Sagalowsky AT, Peters PC, Long-term patient survival after cystectomy for regional metstatic transitional cell carcinoma of the bladder. J Urol 1991; 146: 36-9
55. Scatoni P, Da Pozzo L, Nava L et al. Five year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer. Eur Urol 1995; 28: 102-7
56. Sternberg CN, Raghavan D, Ohi Y et al. Neoadjuvant and adjuvant chemotherapy in advanced disease - What are the effects on survival and prognosis. Int J Urol 1995: 2: 76-88
57. 7 Levine EG, Raghavan D, MVAC for bladder cancer: time to move forward again. J Clin Oncol 1993; 11: 387-9
58. Raghavan D, New strategies for chemotherapy of bladder cancer. Seventh International Congress on Anti-Cancer Treatment. Paris. Feb. 3-6 1997: Abstr. EL39
59. Roth BJ, Dreicer R, Einhorn LH et al. Paclitaxel in previously untreated advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (ECOG). Prof Am Soc Clin Oncol 1994; 13: 230
60. Seligman PA, Crawford DE, Treatment of advanced transitional cell carcinoma of the bladder with continuous infusion gallium nitrate. J Natl Cancer Inst 1991; 83: 1582-4
61. Witte R, Loehrer P, Dreicer R, Williams S, EIson P, Ifosfamide (IFX) in advanced urothelial carcinoma: an ECOG trial. Proc Am Soc Clin Oncol 1993: 12: 230
62. Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ, Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 1994: 12: 2271-6
63. Pollera CF, Ceribelli A, Crecco M, Calabresi F, Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994: 5: 182-4
64. Raghavan D, Editorial: Perioperative chemotherapy for invasive bladder cancer -What should we tell our patients? J Urol 1996; 155: 1246-7
65. Abol-Enein H, El-Mekrech M, El-Baz M, Ghoneim MA, Neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomized study. Er] Urol 1997; 80: abstract 191